Kidney Cancer Journal 41
new safety signals. Clinical trial information: NCT02133742.
Research Funding: Pfizer
n Abstract 5082: Immune infiltration and angio-
genesis as markers of outcome in the post-
nephrectomy setting: Transcriptomic data from
patients receiving placebo on a randomized phase
III trial (PROTECT). A. Ari Hakimi, Martin H Voss, Fengshen
Kuo et al.
Results: Tumors from 236 patients were available for
analysis. Overall, 37% developed metastatic recurrence
and 81% were alive at last follow up. On univariate
analysis increasing tumor stage, higher UISS score, and
angiogenesis/myeloid subgroups (high – H and low – L)
were associated with worse DFS and OS (all p values
<0.05). On multivariate analysis TME subgroups remained
significant for worse DFS and OS (Table).
Conclusions: Microenvironmental subgroups stratified
into angiogenic and myeloid expression profiles carry
independent prognostic significance and should be further
explored to guide future biomarker-directed adjuvant
trials. Clinical trial information: NCT01235962.
Research Funding: Novartis, Philantropic KCJ
Let’s Get
Moving.
Nearly 74,000 people are diagnosed with kidney cancer each year.
We are matching dollar for dollar to raise $74,000 for kidney cancer research!
Are you up for the challenge?
JOIN THE 74KCHALLENGE
KidneyCancer.org
/KidneyCancer.org